Our core values are driven by a desire to improve life, achieve scientific excellence, operate with the highest standards of integrity, expand access to our products and employ a diverse workforce that values collaboration.
We’ve done great things in the past. Today, we’re doing great things for the future.
MSD has a long and rich history of working to improve people’s health and well-being. Through the years, our researchers have helped to find new ways to treat and prevent illness – from the discovery of vitamin B1, to the first measles vaccine, to cold remedies and antacids, to the first statins to treat high cholesterol. Our scientists also have helped develop many products to improve animal health, including vaccines and antibiotics.
While we are proud of our past, we are enthusiastic about the future of our company and we are excited to help create a healthier, brighter future for people around the world.
Beaver Tamesis, Managing Director at MSD Philippines, discusses the company’s impressive growth in recent years as well as their expanding portfolio. Additionally, he discusses his work to foster engagement and…
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
The latest from Southeast Asian pharma, including soaring output in Singapore, tax breaks for research in Indonesia, Thai firm Factorytalk’s UK expansion, and the potential for a Russian COVID-19 vaccine…
The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Ramon Aristoza, acting President and CEO of PhilHealth, discusses the current challenges the organization is facing in terms of realizing the goal of universal healthcare for the Filipino population, their…
We use cookies to ensure that we give you the best experience on our site. For more info